Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "blood routine to return to normal" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "clinical symptoms" assertion.
- OBJECT label "Demographic and laboratory data from the electronic medical record" assertion.
- OBJECT label "Demographic and laboratory data from the electronic medical record" assertion.
- OBJECT label "measured" assertion.
- OBJECT label "at the discretion of the treating physicians to patients with a clinical picture compatible with cytokine release syndrome" assertion.
- OBJECT label "higher levels of interleukin-6" assertion.
- OBJECT label "to death or hospital discharge" assertion.
- OBJECT label "with a clinical picture compatible" assertion.
- OBJECT label "infectious complications and interleukin-6 levels at different points in time" assertion.
- OBJECT label "African - American" assertion.
- OBJECT label "a similar trajectory" assertion.
- OBJECT label "with a trend toward increased risk of infection" assertion.
- OBJECT label "into culture positive and culture negative clinically suspected and treated " assertion.
- OBJECT label "We" assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "statistically significant 94.12 % vs. 87.10 %" assertion.
- OBJECT label "statistically significant 94.12 % vs. 87.10 %" assertion.
- OBJECT label "statistically significant 94.12 % vs. 87.10 %" assertion.
- OBJECT label "statistically significant 94.12 % vs. 87.10 %" assertion.
- OBJECT label "statistically significant 94.12 % vs. 87.10 %" assertion.
- OBJECT label "statistically significant 94.12 % vs. 87.10 %" assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID-19" assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID-19" assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID-19" assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID-19" assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID-19" assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID-19" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "Tocilizumab" assertion.
- OBJECT label "outcome" assertion.
- OBJECT label "outcome" assertion.
- OBJECT label "outcome" assertion.